机构:[1]Department of Oncology, Clinical and Basic Research Team of Traditional Chinese Medicine Prevention and Treatment ofNon-Small Cell Lung Cancer, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China,大德路总院肿瘤科广东省中医院[2]Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China,广东省中医院[3]Guangdong Provincial Key Laboratory of ClinicalResearch on Traditional Chinese Medicine Syndrome, Guangzhou, China,[4]Guangdong Pharmaceutical University,Guangzhou, China
MicroRNA-24 (miR-24) has been widely studied in a variety of human cancers, which plays different roles in specific type of cancers. In the present review, we summarized the recent surveys regarding the role of miR-24 in different human cancers. On the one hand, miR-24 was reported to be down-regulated in some types of cancer, indicating its role as a tumor suppressor. On the other hand, it has shown that miR-24 was up-regulated in some other types of cancer, even in the same type of cancer, suggesting the role of miR-24 being as an oncogene. Firstly, miR-24 was dysregualted in human cancers, which is related to the clinical performance of cancer patients. Thus miR-24 could be used as a potential non-invasive diagnostic marker in human cancers. Secondly, miR-24 was associated with the tumor initiation and progression, being as a promoter or inhibitor. Therefore, miR-24 might be an effective prognostic biomarker in different type of cancers. Lastly, the abnormal expression of miR-24 was involved in the chemo- and radio- therapies of cancer patients, indicating the role of miR-24 being as a predictive biomarker to cancer treatment. Totally, miR-24 contributes to tumorigenesis, tumor progression, and tumor therapy, which closely related to clinic. The present review shows that miR-24 plays a double role in human cancers and provides plenty of evidences to apply miR-24 as a potential novel therapeutic target in treating human cancers.
基金:
Chinese medicine science and technology research project of Guangdong Provincial Hospital of Chinese Medicine [YN2019QJ06, YN2016QJ03]; Guangdong medical science and Technology Research Foundation [A2018251]; Key Top-ranking Discipline Projects of Guangzhou University of Chinese Medicine [A1260619111001]; Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome [ZH2020KF03]; Science and Technology Planning Project of Guangdong Province [2017B030314166]
第一作者机构:[1]Department of Oncology, Clinical and Basic Research Team of Traditional Chinese Medicine Prevention and Treatment ofNon-Small Cell Lung Cancer, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China,[2]Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China,[3]Guangdong Provincial Key Laboratory of ClinicalResearch on Traditional Chinese Medicine Syndrome, Guangzhou, China,
共同第一作者:
通讯作者:
通讯机构:[1]Department of Oncology, Clinical and Basic Research Team of Traditional Chinese Medicine Prevention and Treatment ofNon-Small Cell Lung Cancer, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China,[2]Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China,[3]Guangdong Provincial Key Laboratory of ClinicalResearch on Traditional Chinese Medicine Syndrome, Guangzhou, China,
推荐引用方式(GB/T 7714):
Wang Sumei,Liu Nayan,Tang Qing,et al.MicroRNA-24 in Cancer: A Double Side Medal With Opposite Properties[J].FRONTIERS IN ONCOLOGY.2020,10:doi:10.3389/fonc.2020.553714.
APA:
Wang, Sumei,Liu, Nayan,Tang, Qing,Sheng, Honghao,Long, Shunqin&Wu, Wanyin.(2020).MicroRNA-24 in Cancer: A Double Side Medal With Opposite Properties.FRONTIERS IN ONCOLOGY,10,
MLA:
Wang, Sumei,et al."MicroRNA-24 in Cancer: A Double Side Medal With Opposite Properties".FRONTIERS IN ONCOLOGY 10.(2020)